N@N

Presentation of Two Research Reports Involving Daxor's Blood Volume Analyzer at the 32nd Annual Meeting of the Society of Cardi

^{Published on 2010-05-07 05:40:51 - Market Wire}
 

NEW YORK, NY--(Marketwire - May 7, 2010) - Daxor Corporation (NYSE Amex: [ DXR ]), a medical instrumentation and biotechnology company, today announced that two research reports were presented at the 32^nd annual Society of Cardiovascular Anesthesiologists (SCA) conference in New Orleans, LA which involved the Daxor Blood Volume Analyzer (BVA-100). The BVA-100 enables measurement of whole blood volume, including plasma volume and red blood cell volume. The Principal Investigator for these studies was Mark Nelson, MD, from the Virginia Commonwealth University. These presentations can be viewed on Daxor's website at [ www.daxor.com/sca2010.asp ].

The objective of these studies was to monitor changes in red blood cell volume and total blood volume throughout elective cardiac surgery, including cardiac bypass surgery and/or valve replacement/repair. The hypothesis was that red blood cell volume would be well conserved throughout surgery due to cell salvage and transfusion practices employed in the operating room. Direct blood volume measurements were performed on 46 patients: (1) before surgery; (2) immediately after surgery; and (3) 2 hours after transfer to the intensive care unit. One of the studies, entitled "Red Cell Mass is Not Well Conserved Following Elective Cardiac Surgery Despite Use of Cell Salvage and Transfusion Guided by Peripheral Hematocrit" showed that patients experienced an average net loss of 648 mLs of red blood cell volume as a result of surgery, which is equivalent to more than 2 units of packed red blood cells. These findings revealed a much higher loss of blood than was anticipated, particularly in male patients.

Another study, entitled "Patients are Not Normovolemic Following Cardiac Surgery Despite Concerted Efforts to Manage Fluid and Volume Status" showed that the majority of patients enter surgery in a volume expanded state, largely as the result of pre-surgical fluid infusions. Following surgery, however, the majority of patients showed significantly reduced blood volumes -- despite the fact that commonly used invasive monitoring technology indicated that these patients had been restored to normal blood volumes by careful fluid management.

These pioneering studies are, to our knowledge, the first to directly measure patients' blood volumes throughout the course of surgery, rather than relying on surrogate measures to provide an approximation of patients' volume status. The findings are extremely important as they demonstrate that the standard surrogate measures upon which transfusions and fluid resuscitation decisions are based are not accurate. Surgeons who rely on imprecise surrogate measures of volume status may undertransfuse their patients with fluids and red blood cells, which increases the likelihood that patients will experience post-surgical complications or diminished survival. One of Daxor Corporation's goals is to demonstrate the benefits of direct blood volume measurement in guiding fluid management and blood transfusions during surgery. Such findings could result in blood volume analysis becoming the standard of care to guide fluid resuscitation in a variety of surgical procedures.

The following investigators were involved in these studies: Mark Nelson, MD, Bruce Spiess, MD, Pingle Reddy, MD, John Kearney, MD, Jeff Green, MD, Patricia Nicolato, MD, Derek Brinster, MD, and Vigneshwar Kasirajan, MD. Further details about this research are available on Daxor's website.

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website [ www.Daxor.com ].